Sivia Capital Partners LLC Reduces Stake in Novo Nordisk A/S (NYSE:NVO)

Sivia Capital Partners LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 11.0% during the fourth quarter, Holdings Channel reports. The firm owned 7,949 shares of the company’s stock after selling 978 shares during the quarter. Sivia Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $684,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NVO. Novare Capital Management LLC grew its stake in Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after acquiring an additional 85 shares during the last quarter. Steel Grove Capital Advisors LLC grew its position in shares of Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after purchasing an additional 86 shares during the last quarter. Benjamin Edwards Inc. increased its stake in shares of Novo Nordisk A/S by 2.6% during the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock worth $493,000 after purchasing an additional 87 shares in the last quarter. Rosenberg Matthew Hamilton raised its position in shares of Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock worth $454,000 after purchasing an additional 94 shares during the last quarter. Finally, Burns J W & Co. Inc. NY lifted its stake in Novo Nordisk A/S by 1.9% in the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock valued at $647,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.5 %

NVO stock traded down $2.15 during midday trading on Monday, reaching $84.11. 6,033,316 shares of the company’s stock traded hands, compared to its average volume of 7,204,707. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The business has a 50-day moving average price of $100.35 and a two-hundred day moving average price of $119.04. The company has a market capitalization of $377.45 billion, a P/E ratio of 27.22, a PEG ratio of 1.37 and a beta of 0.45.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.